Replies to post #222912 on Innovation Pharmaceuticals Inc (IPIX)

[FlashingLeather]

I don't expect a B deal to close unless one of the following events occurs:
1) P results disappoint
2) a potential partner brings something absolutely critical (other than cash) to B's further development
3) BP rings the bell at Leo's numbers

When IPIX adopted their value maximization strategy a couple of years ago, I think it was fairly obvious that the intent was to partner with P first, if possible. They had not even started the B-UP trial at that point in time. Business conditions have changed since then, as they always do, and timing of all the trial data has made the potential for a B deal a viable possibility; however I haven't seen anything happen as yet that would necessitate a modification of their original plans.

I think Leo's strategy is simple at the moment. His numbers right now for anything B-related are high...quite high. He moves all options forward as much as he can but doesn't decide on a definitive path forward until he is certain of the P results. If they're good and he deems a P deal likely, he'll pursue that route rather quickly. It's likely he has a few players lined up for a fast look and decision on the data. If P disappoints, he'll drop his numbers for B, and get something done with that asset.

[MinnieM]

Actually, a deal for the entire company may be held up for Prurisol results. Those results may impact negotiated price.

Either way, for a variety of reasons, deals take longer than most realize. And, most aren't publicly known in advance.





In Reply to 'frrol'
P results would not be holding up a B partnership. A B partnership would, however, be held up by an FDA meeting if we applied for BTD. And a BTD decision takes up to 60 days after a request is made and all required data is submitted. There is value in BTD so I suspect this is the hold-up, if a deal is pending. Just gotta have patience and wait and see. I am 100% certain this management is pushing for a deal. It is the most reasonable path forward given our high cost of capital (ie relatively low share price) and lack of market confidence in the company. The company has openly acknowledged the former repeatedly.

We have an upcoming meeting with the FDA. Let's see.